Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FightMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

Name: Gene name corresponding to the UniProt ID
UniProt ID: UniProt accession number
Publication: Study Reference
Condition: e.g.ALS – Control, ALS Fast – ALS Slow
Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
Regulation: Direction of change (upregulated or downregulated)
Cohorts: Cohort size used for each study
Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI: _____

Contact: For help contact rachel.tan1@sydney.edu.au

Biomarker Name

UniProt ID

Condition

Publication

Sample Type

Sort by:

Ascending Descending

Total Records Found: 2896, showing 100 per page
Biomarker Name	UniProt ID	Publication	Condition	Sample Type	Regulation	Cohorts	Average age at onset	Average age at collection	Average PMI
GAL3ST4	Q96RP7	Oeckl et al. 2020	sALS – Control	CSF	Up	12 ALS, 16 control	66 (57-68)	67 (58-74)
GAL3ST4	Q96RP7	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Up	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GABRB2	E7EV50	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
GABBR2	O75899	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Down	8 ALS, 8 control	60	63.5	9.1
GABARAPL2	H3BSM5	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
GABARAPL2	P60520	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GAA	P10253	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
GAA	P10253	Zhou et al. 2023	BO-ALS – Control	CSF	Up	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
G6PD	P11413	Filareti et al. 2017	Late ALS – Early ALS	PBMCs	Up	4 Early-ALS, 4 Late-ALS		50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS)
G6PD	P11413	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
G3BP2	Q9UN86	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
G3BP2	Q9UN86	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
G3BP1	Q13283	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
FZD8	Q9H461	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
FXYD6	Q9H0Q3	Vassileff et al. 2020	ALS – Control	Motor Cortex EVs	Up	7 ALS, 3 control
FXRD2	Q8IWF2	Andrés-Benito et al. 2020	ALS – Control	CSF	Up	15 ALS, 15 control		61 ± 10.8
FXR2	P51116	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
FUCA2	Q9BTY2	Zhou et al. 2023	BO-ALS – Control	CSF	Up	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
FUCA2	Q9BTY2	Andrés-Benito et al. 2020	ALS – Control	CSF	Up	15 ALS, 15 control		61 ± 10.8
FUCA2	Q9BTY2	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
FUCA2	Q9BTY2	Collins et al. 2015	ALS – Control	CSF	Down	90 ALS, 80 control
FUCA2	Q9BTY2	Oeckl et al. 2020	gALS – Control	CSF	Up	14 gALS, 16 control	54 (52-69)	62 (53-75)
FUBP1	Q96AE4	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
FTH1	P02794	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
FSTL4	Q6MZW2	Collins et al. 2015	ALS – Control	CSF	Down	90 ALS, 80 control
FSTL3	O95633	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
FSD1L	Q9BXM9	Oeckl et al. 2020	ALS – Control	Spinal cord	Down	8 ALS, 7 control		59 (52-61)	36 (24-90)
FSD1	Q9BTV5	Oeckl et al. 2020	ALS – Control	Spinal cord	Down	8 ALS, 7 control		59 (52-61)	36 (24-90)
FRMD3	A2A2Y4	Collins et al. 2015	ALS – Control	CSF	Up	90 ALS, 80 control
FOLR2	P14207	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
FOLR1	P15328	Hayashi et al. 2020	ALS – Control	CSF exosome-enriched fractions	Down	3 ALS, 3 control		74.3
FN1	P02751	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
FMOD	Q06828	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
FLT4	P35916	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
FLNC	Q14315	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8
FLNA	P21333	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
FLNA	P21333	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
FLNA	P21333	Zubiri et al. 2018	ALS fast – ALS slow (late stage)	Plasma	Up	8 ALS-fast, 6 ALS-slow	61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
FLJ53848	B4DM79	Collins et al. 2015	ALS – Control	CSF	Up	90 ALS, 80 control
FLJ43649	Q6ZUJ7	Collins et al. 2015	ALS – Control	CSF	Up	90 ALS, 80 control
FKRP	Q9H9S5	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
FKBP3	Q00688	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
FKBP1A	P62942	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
FHL1	Q13642	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Down	8 ALS, 8 control	60	63.5	9.1
FH	P07954	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
FGG	P02679	Oeckl et al. 2020	ALS – Control	CSF	Up	26 ALS, 16 control
FGG	P02679	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
FGG	P02679	Umoh et al. 2018	ALS – Control	Frontal cortex	Down	19 ALS, 10 control	55	59	10.6
FGG	P02679	Filareti et al. 2017	Late ALS – Early ALS	PBMCs	Up	4 Early-ALS, 4 Late-ALS		50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS)
FGFR2	P21802	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
FGFBP2	Q9BYJ0	Zhou et al. 2023	SO-ALS – Control	CSF	Down	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
FGF12	P61328	Oeckl et al. 2020	ALS – Control	Spinal cord	Down	8 ALS, 7 control		59 (52-61)	36 (24-90)
FGF10	O15520	Berrone et al. 2023	sALS – Control	Plasma	Up	8 sALS, 8 control	62 ± 13 (sALS & fALS)	64 ± 11 (sALS & fALS)
FGF1	P05230	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
FGB	P02675	Oeckl et al. 2020	ALS – Control	CSF	Up	26 ALS, 16 control
FGB	P02675	Umoh et al. 2018	ALS – Control	Frontal cortex	Down	19 ALS, 10 control	55	59	10.6
FGA	P02671	Oeckl et al. 2020	ALS – Control	CSF	Up	26 ALS, 16 control
FGA	P02671	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
FGA	P02671	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
FGA	P02671	Vu et al. 2023	ALS fast – ALS slow	CSF	Up	6 ALS-fast, 5 ALS-slow	54.3 (ALS-fast), 43.4 (ALS-slow)	55.3 (ALS-fast), 52.2 (ALS-slow)
FGA	P02671	Oeckl et al. 2020	sALS – Control	CSF	Up	12 ALS, 16 control	66 (57-68)	67 (58-74)
FGA	P02671	Collins et al. 2015	ALS – Control	CSF	Up	90 ALS, 80 control
FGA	P02671	Umoh et al. 2018	ALS – Control	Frontal cortex	Down	19 ALS, 10 control	55	59	10.6
FGA	P02671	Filareti et al. 2017	Late ALS – Early ALS	PBMCs	Up	4 Early-ALS, 4 Late-ALS		50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS)
FGA	P02671	Oeckl et al. 2020	gALS – Control	CSF	Up	14 gALS, 16 control	54 (52-69)	62 (53-75)
FETUB	Q9UGM5	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
FETUB	Q9UGM5	Vu et al. 2023	ALS fast – ALS slow	CSF	Up	6 ALS-fast, 5 ALS-slow	54.3 (ALS-fast), 43.4 (ALS-slow)	55.3 (ALS-fast), 52.2 (ALS-slow)
FETUB	Q9UGM5	Bereman et al. 2018	ALS – Control	CSF	Up	33 ALS, 30 control
FERMT3	Q86UX7	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
FER	P16591	Berrone et al. 2023	fALS – Control	Plasma	Up	8 fALS, 8 control	62 ± 13 (sALS & fALS)	64 ± 11 (sALS & fALS)
FECH	P22830	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Down	8 ALS, 8 control	60	63.5	9.1
FDXR	A0A0A0MTN9	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
FDPS	P14324	Oeckl et al. 2020	ALS – Control	Spinal cord	Down	8 ALS, 7 control		59 (52-61)	36 (24-90)
FCN3	O75636	Vu et al. 2023	ALS fast – ALS slow	CSF	Up	6 ALS-fast, 5 ALS-slow	54.3 (ALS-fast), 43.4 (ALS-slow)	55.3 (ALS-fast), 52.2 (ALS-slow)
FCN3	O75636	Zubiri et al. 2018	ALS fast – ALS slow (early stage)	Plasma	Down	8 ALS-fast, 6 ALS-slow	61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
FCN3	O75636	Xu et al. 2018	ALS – Control	Plasma	Up	42 ALS, 18 control		61.8 ± 9.6
FCGR3A	P08637	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
FCGR3A	P08637	Oeckl et al. 2020	gALS – Control	CSF	Up	14 gALS, 16 control	54 (52-69)	62 (53-75)
FCGR2A	P12318	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Up	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
FCGBP	Q9Y6R7	Hayashi et al. 2020	ALS – Control	CSF exosome-enriched fractions	Down	3 ALS, 3 control		74.3
FCER2	P06734	Berrone et al. 2023	sALS – Control	Plasma	Down	8 sALS, 8 control	62 ± 13 (sALS & fALS)	64 ± 11 (sALS & fALS)
FBXO2	Q9UK22	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8
FBXO2	Q9UK22	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
FBXL17	Q9UF56	Collins et al. 2015	ALS – Control	CSF	Down	90 ALS, 80 control
FBXL15	Q9H469	Oeckl et al. 2020	ALS – Control	Spinal cord	Down	8 ALS, 7 control		59 (52-61)	36 (24-90)
FBN1	P35555	Chen et al. 2016	ALS – Control	CSF	Down	35 ALS, 10 control		52.7 ±12.13
FBLN7	Q53RD9	Zhou et al. 2023	BO-ALS – Control	CSF	Up	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
FBLN7	Q53RD9	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
FBLN5	Q9UBX5	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
FBLN1	P23142	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
FBLN1	P23142	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
FBLN1	P23142	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
FBLN1	P23142	Katzeff et al. 2020	ALS – Control	Serum	Down	28 ALS, 22 control		52.7
FAT2	Q9NYQ8	Bereman et al. 2018	ALS – Control	CSF	Down	33 ALS, 30 control
FASN	P49327	Umoh et al. 2018	ALS – Control	Frontal cortex	Down	19 ALS, 10 control	55	59	10.6
FASN	P49327	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
FARSB	Q9NSD9	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
FARSB	Q9NSD9	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
FARSA	Q9Y285	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
FARSA	Q9Y285	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)